Significance of Calorie-Restricted Ketogenic Diet for Lung Cancer with Brain Metastases and Hepatoma with Pulmonary Metastases: Two Case Reports

Article Information

Dong Tan1*, Jing Zhao2,  Wen-ru Yang1, Fang Yuan1

1Department of General Practitioner, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, 266035, China.

2Cambridge Stem Cell Institute, University of Cambridge, CB2 0AW, UK

*Corresponding author: Dong Tan, Department of General Practitioner, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, 266035, China.

Received: 23 August 2022; Accepted: 06 September 2022; Published: 14 September 2022

Citation: Dong Tan, Jing Zhao, Wen-ru Yang, Fang Yuan. Significance of Calorie-Restricted Ketogenic Diet for Lung Cancer with Brain Metastases and Hepatoma with Pulmonary Metastases: Two Case Reports. Archives of Clinical and Biomedical Research 6 (2022): 807-812.

View / Download Pdf Share at Facebook


Background: Cancer cells have altered metabolism that is characterized by an enhanced uptake and utilization of glucose. These increased glucose dependence alterations, present potential vulnerabilities that could be targeted for cancer therapy. The calorie-restricted ketogenic diet (KD) may meet the requirement.

Case Presentation: We present two cases of patients diagnosed with aggressive forms of cancer, lung cancer with brain metastatic tumors and primary liver cancer with pulmonary metastases. The patients began KD intervention after exhausting the other treatment options. Both of them responded to KD and demonstrated a beneficial effect. The tumor size from serial imaging and serum tumor markers were significantly reduced after KD in both subjects without any adverse effects. Both patients had tumour remission even after stopping the ketogenic diet, indicating that KD is a safe, effective treatment to aggressive cancers with metastases when used with conventional therapies. Conclusions: This study demonstrated the significant beneficial effect of a calorie-restricted ketogenic diet for two types of aggressive cancers with metastases. Even a brief KD intervention has a profound effect, implicating the significant therapeutic potential for the ketogenic diet as adjuvant therapy for cancer treatment.


Cancer; Calorie Restriction; C24-27ase Report; Ketogenic Diet; Metastases; Warburg Effect

Cancer articles; Calorie Restriction articles; C24-27ase Report articles; Ketogenic Diet articles; Metastases articles; Warburg Effect articles

Article Details


AFP- Alpha Fetoprotein; ALK- Anaplastic Lymphoma Kinase; CA- Carbohydrate Antigen; CEA- Carcinoembryonic Antigen;  CgA- Chromogranin A; CK7- Cytokeratin 7; CT- Computerised Tomography; DWI- Diffusion Weighted Imaging; EML4- Echinoderm Microtubule-Associated Protein-Like 4; FLAIR- Fluid-Attenuated Inversion Recovery; KD- Ketogenic Diet; Ki67- Antigen KI-67; MRI- Magnetic Resonance Imaging; NSE- Neuron-Specific Enolase; Syn- Synaptophysin; TTF-1- Thyroid Transcription Factor 1

1. Background

The metabolism of cancer cells differs significantly from that of normal cells and these differences play an important role in tumorigenesis [1]. In cancer cells, most energy comes from the conversion of glucose to lactate, even in the presence of normal levels of oxygen. This metabolic shift from oxidative phosphorylation to glycolysis is known as the Warburg effect [1]. The Warburg effect exposes fundamental vulnerabilities of cancer cells reliance on excess glucose for survival and proliferation. Under the glucose deprivation condition, cancer cells are not capable to switch to ketone bodies as a substitute for energy, due to mitochondrial dysfunction and down-regulation of enzymes necessary for ketone utilization [2]. Lacking the metabolic flexibility of cancer cells presents a therapeutic potential for cancer treatment. The Ketogenic Diet (KD), a high-fat/low-carbohydrate/adequate-protein diet that originally used to treat epilepsy [3, 4], has recently been suggested as adjuvant therapy in cancer treatment [5, 6]. KD aims at the Warburg effect, causing cancer cell death by glucose starvation while normal cells adapt their metabolism to utilize ketone bodies as a substitute for energy, on which normal cells survive. Furthermore reducing blood glucose is also associated with reduced levels of insulin and insulin-like growth factor, which play an important role in cancer cell proliferation [7]. Numerous preclinical studies have provided evidence for an anti-tomour effect of KD [5, 6, 8-12]. The clinical potential of KD in the treatment of cancer has only recently been explored. Most of the clinical data are from case reports [13-17] or pilot studies mainly focusing on the safety of the KD [18, 19]. Only one randomized controlled trial is available to date [20]. The results of these clinical trials were encouraging, specifically for brain tumour [5, 13, 14]. Importantly no serious adverse effect or toxicity related to KD intervention in these studies. We present here two case studies of patients diagnosed with lung cancer with intracranial metastatic tumours and primary liver cancer with pulmonary metastases. Both patients started KD after failed conventional treatments. Our study confirmed the beneficial effect of KD in cancer treatment.

2. Case Presentation

2.1 Case One

A 32 years old female who was six months pregnant had experienced cough without obvious inducement in 2012. The cough was dry and not accompanied by sputum, chest tightness and wheezing or fever. At that time, the patient did not seek any medical advice, diagnosis or treatment. The cough was relieved after giving birth. A few months after giving birth, the patient began to experience cough symptoms again with white phlegm, however, no diagnosis or treatment was given. After that, the patient's cough was aggravated, accompanied by chest tightness and asthma. Chest CT examination in the affiliated hospital of Qingdao University showed multiple plaques and consolidation in both lungs where fluid dark areas were visible and a large amount of pleural effusion was on the left side. No swelling of mediastinal lymph nodes was observed. Laboratory test results showed that carcinoembryonic antigen (CEA) at 50.05ng /ml, neuron-specific enolase (NSE) 18.96ng /ml, cancer antigen (CA) 125 61.67u /ml and erythrocyte sedimentation rate 67mm/h. Closed thoracic drainage was given and fluid drainage had a reddish-brown appearance. About a total of 1000ml of fluid was drained out. Concurrent puncture biopsy confirmed invasive adenocarcinoma. The patient was then admitted to our hospital. Chest CT images collected in 19th November 2014 showed multiple and high lung density, which was consistent with the previous CT findings of lung cancer, as well as left pleural effusion and left inferior lobe atelectasis (Figure 1). Lung biopsy confirmed invasive adenocarcinoma, and laboratory test results showed elevated tumour markers: CEA 16.08ng/ml; carbohydrate antigen 125 (CA-125) 63.80U/ml; cancer antigen 15-3 (CA15-3) 79.62U/ml. During the hospitalization, the patient's condition gradually worsened, with continuous intermittent fever, accompanied by repeated chest tightness and suffocation. Despite anti-infection therapy was given, the patient's condition was still progressive aggravation. A panel of immunohistochemistry staining showed: TTF-1 (+), CK7(+), Syn(-), CgA(-), Ki67 positive rate was about 5%, EML4-ALK variant 1 (gene fusion point E13; A20) and variant 3a/b (gene fusion point E6aE; A20) were positive. Crizotinib (200mg bid) was given on 13th December 2014, and the patient's symptoms gradually improved. The patient was readmitted one year later after complaining of headache and nausea on 24th February 2016. Brain MRI scan obtained on 26th February 2016 revealed multiple lesions, indicating brain metastases (Figure 2). DWI and FLAIR images showed multiple metastatic lesions with peripheral edema with the brain parenchyma. The patient was instructed to a strict KD together with continued Crizotinib treatment on 3rd March 2016. No apparent ketosis or significantly decreased blood sugar was observed during KD interventions. Although the patient only had the strict KD for two and a half months due to feeling unable to tolerant the strict diet, the clinical symptoms and signs were remarkably improved. Both the chest CT scan and brain MRI scan showed significant changes. All the previous lesions in the lungs (Figure 3A-C) and brain (Figure 4) were deceased gradually by days. Pulmonary lesions were almost complete resolution two months after KD on 3rd May 2016 and showed no recurrent tumour in follow-up chest scan on 8th May 2017 (Figure 3A-C). Brain metastatic lesions were almost undetectable six months after KD and complete resolution in subsequent brain MRI scans performed on 29th September 2016 and 8th May 2017 (Figure 4). The lasted chest CT and brain MRI performed in December 2019 did not show any abnormal nodules (data not shown), indicating the patient had remission nearly 4 years after treatments. Consistent with the tumour volume, the levels of serum tumour markers declined gradually and finally fell within the normal range with CEA 2.2 ng/ml, CA-125 25.41 and CA15-3 16.92 in 18th December 2016) (Figure 3D-F).


Figure 1: Chest CT scan from the female patient in Case 1 on 19th November 2014. Suspected lung cancer with bilateral multifocal consolidations revealed by an initial anterior-posterior chest radiograph (A), CT scan in lung window (B) and CT scan in a soft-tissue window (C, D).


Figure 2: Brain MRI from the female patient in Case 1 on 26th February 2016. The T2-weighted MRI (A) and T1-weighted MRI (B) reveal multiple well-defined lesions. DWI (C) shows the metastatic lesions with peripheral edema within the brain parenchyma and FLAIR image (D) shows multiple enhancing metastatic lesions.


Figure 3: Changes in the tumour volume and tumour markers of the patient 1 after KD intervention. Chest CT scans revealed multifocal consolidations with ground-glass opacity before KD on 18th November 2014 (A); almost complete resolution of the lesions one and half years after KD on 3rd May 2016 (B); complete remission two and half years after KD on 8th May 2017 (C); The serum levels of carcinoembryonic antigen (CEA) (D); carbohydrate antigen 125 (CA-125) (E); and carcinoembryonic antigen 15-3 (CA 15-3) (F); changed over time and decreased after KD intervention.


Figure 4: Brain MRI from the female patient in Case 1. FLAIR images show several metastatic lesions (red arrows) on 26th February 2016 (A) before KD intervention; almost complete resolution of the lesions two months after KD on 29th September 2016 (B); completely remission after KD on 8th May 2017 (C) and on 27th March 2019 (D).

2.2 Case Two

A 47 years old female patient had a history of hepatitis B for 23 years and was admitted to the hospital for 6 days due to right upper abdominal pain. On 15th July 2018, a screening test showed that the levels of alpha fetoprotein (AFP) level in the blood were elevated, AFP≥2000ng/ml, ferritin 210.24ng/ml, and neuron-specific enolase 25.20ng/ml. Chest CT showed double pulmonary fibre foci. Abnormal intrahepatic density was also observed. Two days later, enhanced CT scan was performed to confirm the lesion of liver mass, which was consistent with the manifestations of liver cancer. The left lobe of the liver was removed on 21st July 2018. Liver pathological examination results showed grade II hepatocellular carcinoma and nodular cirrhosis. The patient recovered well after surgery and was discharged 10 days later. No special follow-up treatment was administered. After discharge from the hospital, the patient continuously monitored AFP index in the blood and found that there was a constant increase. AFP level reached 5713 ng/ml on 21st December 2018. CT scan revealed multiple enhanced nodules in the abdominal liver, suggesting tumour recurrence. Multiple nodular lesions were detected in the middle and lower lobes of the lung on 20th November 2018 (Figure 5A-D), indicating pulmonary metastases. Considering the aggressive nature of cancer and limited treatment options available, the patient was instructed to start a ketogenic diet on 21st December 2018. The proportion of fat in the dietary was approximate 30%; the proportion of protein was approximately 50-60%; the proportion of vegetable and cellulose was approximately 10-20%. The patient came off KD after one month since she found it difficult to maintain the strict KD. No apparent ketosis or significantly decreased blood sugar was observed during KD interventions. After one month of strict KD, AFP levels reduced to 512ng/ml. AFP levels fell within a normal range at 3.01ng/ml two months later and maintained AFP levels 1.41ng/ml half a year later (Figure 6). Consistent with this, the CT scan revealed much reduced pulmonary nodules d in the middle lobes of the lung and no residual nodules detected in the lower lobes of the lung on 24th July 2019 (Figure 5E-H). The latest scan images collected on 20th December 2019 showed no recurrent tomour (data not shown), indicating that the tumour in complete remission one and a half years after KD.


Figure 5: Chest CT scans in lung window of the female patient in Case 2. Multiple pulmonary nodules (red arrows), due to metastases, detected in the middle (A, B) and lower (C, D) lobes of the lung on 20th November 2018. One year after KD intervention. Much reduced pulmonary nodules observed in the middle (E, F) and no pulmonary nodules detected in the lower (G, H) lobes of the lung on 24th July 2019.


Figure 6: Ketogenic diet reduces serum alpha feta protein (AFP) level. AFP level decreased in response to KD and fell into a normal range. Black arrow indicates the date that the patent began the ketogenic diet.

3. Discussion and Conclusions

Cancer metabolism is an essential aspect of tumorigenesis and is one of the oldest research areas in cancer biology [21]. Despite a broad range of metabolic alterations has been reported in tumours recently the Warburg effect is still the most recognized metabolic characteristic of many cancer cells [1]. Tumour proliferation and survival are dependent upon these metabolic changes to provide the excess needs for glucose [1]. The altered metabolism in cancer cells, therefore, provided a unique therapeutic target to treat cancer. This study explored the feasibility of calorie-restricted KD to target the Warburg effect in the treatment of patients with cancer. Nutrient sensing is essential for cell survival and a regulator for cell function. Cellular homeostasis is maintained by sensing changes in nutrient availability, followed by adaptive responses [22]. While normal cells metabolise glucose for energy under normal physiological conditions, they can utilise ketone bodies a substitute for glucose when blood glucose levels decrease [23, 24]. The dynamic metabolic adaptation is particularly critical for brain function and cognition. Ketone bodies can cross the blood-brain barrier and play a vital role as energy substrates for the brain, especially during times of starvation and in early childhood brain development [25-27]. Ketones can provide as much as 70% of the brain's energy needs, more efficiently than glucose [28]. Tumour cells, however, lack the dynamic metabolic adaptation. The result is that the cancer cells become heavily dependent on glucose and are unable to utilize the ketones as a substitute for glucose. It has been shown that higher glucose could enhance cancer aggressiveness [29]. A “vicious cycle” may exist within the cancer cells which is that glucose drives cancer progress whilst metabolic changes in cancer may favour glucose delivery to cancer cells [30]. Restriction of glucose will break this vicious cycle thereby inhibit tumour progression. Two patients with aggressive forms of cancers were recruited for our study, a 32-year-old lung cancer patient with brain metastases, and a 47-year-old liver cancer patient with pulmonary metastases. Both patients had poor prognoses. A strict KD was administered to them after they had exhausted the conventional anti-tumour treatment options. They demonstrated excellent therapeutic responses to KD. Both patients had improved clinical symptoms and the tumour size reduced progressively without adversely affecting the patient's overall nutritional status. Although patients were only on KD for two and a half months for the patient with brain metastases in lung cancer, and one month for the patient with pulmonary metastases in liver cancer, the anti-tomour effect of KD was evident and long-lasting. The recent physical exams and scan images revealed that the cancers had gone into remission in both patients despite both of patients discontinuing the KD. This profound and lasting beneficial effect of KD may be due to the following reasons: 1) KD targets the Warburg effect, limits the glucose availability and selectively starves tomours. It is particularly effective for the aggressive forms of cancers where excess glucose is required to support tumour proliferation and progression. 2) After initial reducing the tumour size and slowing the tumour growth rate, the immune system could match the rate of tumour proliferation, regain control over tomour growth and establish a new stage of equilibrium. 3) It has been reported that KD could act as an immune adjuvant, increase tomour-reactive innate and adaptive immune responses [31]. 4) KD may not only be responsible for the restriction of nutrient uptake in tomour cells, but Ketone bodies may also influence the epigenetic regulation of gene expression, involving several possible downstream pathway interactions to inhibit the tumour growth and proliferation. Indeed, the previous studies showed that KDs could influence the patterns of gene expression in tomours [32, 33]. The long-lasting beneficial effect of KD on cancer patients suggests a synergistic action of KD. In conclusion, we have demonstrated the significant beneficial effect of a calorie-restricted ketogenic diet for two types of aggressive cancers with metastases. Even a brief KD intervention has a profound effect, implicating the significant therapeutic potential for KD, especially for the fast-growing and aggressive forms of cancers. Compared to other anti-cancer drugs and standard treatment, KD is safe, effective, inexpensive and easy to implement. With recently much improved KD recipes, KD may warrant routine application as adjuvant therapy in cancer treatment in future. 


We thank the participants for their contributions to this study.

Authors' Contributions

DT carried out designed the study, responsible for the patient management, analysis the data and drafted the manuscript. JZ helped reviewed and revised the manuscript and contributed to the discussion. WRY and FY participated in the patient management and clinical data collection. All authors read and approved the final manuscript.


This work was supported by Department of General Practitioner, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University.

Availability of Data and Materials

The data used in this study are available from the corresponding author on request.

Ethics Approval and Consent to Participate

The study protocol was approved by the Ethics Committee of the Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University (Reference number: qdql2020004). Written informed consent was obtained from each study subject.

Consent for Publication

The authors declare that the patients described in the case presentation have given their written consents for their personal or clinical details along with any identifying images to be published in this study. A copy of the consent form is available for review by the editor of this journal.

Competing Interests

The authors declare that they have no competing interests.


  1. Weyandt JD, Thompson CB, Giaccia AJ, et al. Metabolic Alterations in Cancer and Their Potential as Therapeutic Targets. Am Soc Clin Oncol Educ Book 37 (2017): 825-832.
  2. Klement RJ, Kammerer U. Is there a role for carbohydrate restriction in the treatment and prevention of cancer? Nutr Metab (Lond) 8 (2011): 75.
  3. Nei M, Ngo L, Sirven JI, et al. Ketogenic diet in adolescents and adults with epilepsy. Seizure 23 (2014): 439-442.
  4. Li HF, Zou Y, Ding G. Therapeutic Success of the Ketogenic Diet as a Treatment Option for Epilepsy: a Meta-analysis. Iran J Pediatr 23 (2013): 613-620.
  5. Klement RJ. Fasting, Fats, and Physics: Combining Ketogenic and Radiation Therapy against Cancer. Complement Med Res 25 (2017): 102-113.
  6. Weber DD, Aminzadeh-Gohari S, Tulipan J, et al. Ketogenic diet in the treatment of cancer - Where do we stand? Mol Metab (2019).
  7. Brahmkhatri VP, Prasanna C, Atreya HS. Insulin-like growth factor system in cancer: novel targeted therapies. Biomed Res Int 2015 (2015): 538019.
  8. Morscher RJ, Aminzadeh-Gohari S, Hauser-Kronberger C, et al. Combination of metronomic cyclophosphamide and dietary intervention inhibits neuroblastoma growth in a CD1-nu mouse model. Oncotarget 7 (2016): 17060-17073.
  9. Shukla SK, Gebregiworgis T, Purohit V, et al. Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. Cancer Metab 2 (2014): 18.
  10. Rieger J, Bahr O, Maurer GD, et al. ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol 44 (2014): 1843-1852.
  11. Tisdale MJ, Brennan RA, Fearon KC. Reduction of weight loss and tumour size in a cachexia model by a high fat diet. Br J Cancer 56 (1987): 39-43.
  12. Morscher RJ, Aminzadeh-Gohari S, Feichtinger RG, et al. Inhibition of Neuroblastoma Tumor Growth by Ketogenic Diet and/or Calorie Restriction in a CD1-Nu Mouse Model. PLoS One 10 (2015): e0129802.
  13. Zuccoli G, Marcello N, Pisanello A, et al. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report. Nutr Metab (Lond) 7 (2010): 33.
  14. Strowd RE, Cervenka MC, Henry BJ, et al. Glycemic modulation in neuro-oncology: experience and future directions using a modified Atkins diet for high-grade brain tumors. Neurooncol Pract 2 (2015): 127-136.
  15. Iyikesici MS, Slocum AK, Slocum A, et al. Efficacy of Metabolically Supported Chemotherapy Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy for Stage IV Triple-Negative Breast Cancer. Cureus 9 (2017): e1445.
  16. Branca JJ, Pacini S, Ruggiero M. Effects of Pre-surgical Vitamin D Supplementation and Ketogenic Diet in a Patient with Recurrent Breast Cancer. Anticancer Res 35 (2015): 5525-5532.
  17. Schwartz K, Chang HT, Nikolai M, et al. Treatment of glioma patients with ketogenic diets: report of two cases treated with an IRB-approved energy-restricted ketogenic diet protocol and review of the literature. Cancer Metab 3 (2015): 3.
  18. Iyikesici MS. Feasibility study of metabolically supported chemotherapy with weekly carboplatin/paclitaxel combined with ketogenic diet, hyperthermia and hyperbaric oxygen therapy in metastatic non-small cell lung cancer. Int J Hyperthermia 36 (2019): 446-455.
  19. Tan-Shalaby JL, Carrick J, Edinger K, et al. Modified Atkins diet in advanced malignancies - final results of a safety and feasibility trial within the Veterans Affairs Pittsburgh Healthcare System. Nutr Metab (Lond) 13 (2016): 52.
  20. Cohen CW, Fontaine KR, Arend RC, et al. Favorable Effects of a Ketogenic Diet on Physical Function, Perceived Energy, and Food Cravings in Women with Ovarian or Endometrial Cancer: A Randomized, Controlled Trial. Nutrients 10 (2018).
  21. Pavlova NN, Thompson CB. The Emerging Hallmarks of Cancer Metabolism. Cell Metab 2016, 23(1):27-47.
  22. Hietakangas V, Cohen SM: Regulation of tissue growth through nutrient sensing. Annu Rev Genet 43 (2009): 389-410.
  23. Cunnane SC, Courchesne-Loyer A, St-Pierre V, et al. Can ketones compensate for deteriorating brain glucose uptake during aging? Implications for the risk and treatment of Alzheimer's disease. Ann N Y Acad Sci 1367 (2016): 12-20.
  24. Hasselbalch SG, Knudsen GM, Jakobsen J, et al. Blood-brain barrier permeability of glucose and ketone bodies during short-term starvation in humans. Am J Physiol 268 (1995): E1161-1166.
  25. Nehlig A. Brain uptake and metabolism of ketone bodies in animal models. Prostaglandins Leukot Essent Fatty Acids 70 (2004): 265-275.
  26. Prins ML. Cerebral ketone metabolism during development and injury. Epilepsy Res 100 (2012): 218-223.
  27. Wyss MT, Jolivet R, Buck A, et al. In vivo evidence for lactate as a neuronal energy source. J Neurosci 31 (2011): 7477-7485.
  28. White H, Venkatesh B. Clinical review: ketones and brain injury. Crit Care 15 (2011): 219.
  29. Santos JM, Hussain F. Higher Glucose Enhances Breast Cancer Cell Aggressiveness. Nutr Cancer (2019): 1-13.
  30. Schwartsburd P. Cancer-Induced Reprogramming of Host Glucose Metabolism: "Vicious Cycle" Supporting Cancer Progression. Front Oncol 9 (2019): 218.
  31. Lussier DM, Woolf EC, Johnson JL, et al. Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet. BMC Cancer 16 (2016): 310.
  32. Stafford P, Abdelwahab MG, Kim DY, et al. The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab (Lond) 7 (2010): 74.
  33. Scheck AC, Abdelwahab MG, Fenton KE, et al. The ketogenic diet for the treatment of glioma: insights from genetic profiling. Epilepsy Res 100 (2012): 327-337.

© 2016-2024, Copyrights Fortune Journals. All Rights Reserved